Dermata Therapeutics Stock Analysis

DRMA Stock  USD 0.87  0.05  6.10%   
Dermata Therapeutics is undervalued with Real Value of 2.14 and Target Price of 6.0. The main objective of Dermata Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Dermata Therapeutics is worth, separate from its market price. There are two main types of Dermata Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Dermata Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Dermata Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dermata Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
For information on how to trade Dermata Stock refer to our How to Trade Dermata Stock guide.

Dermata Stock Analysis Notes

About 24.0% of the company shares are held by company insiders. The book value of Dermata Therapeutics was currently reported as 0.62. The company recorded a loss per share of 8.03. Dermata Therapeutics had not issued any dividends in recent years. The entity had 1:15 split on the 16th of May 2024. Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company was incorporated in 2014 and is headquartered in San Diego, California. Dermata Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 8 people. To learn more about Dermata Therapeutics call the company at 858 800 2543 or check out https://www.dermatarx.com.

Dermata Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Dermata Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Dermata Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Dermata Therapeutics generated a negative expected return over the last 90 days
Dermata Therapeutics has high historical volatility and very poor performance
Dermata Therapeutics has some characteristics of a very speculative penny stock
Dermata Therapeutics has a very high chance of going through financial distress in the upcoming years
Net Loss for the year was (12.29 B) with profit before overhead, payroll, taxes, and interest of 0.
Dermata Therapeutics currently holds about 10.63 M in cash with (11.16 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.05, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Dermata Therapeutics has a poor financial position based on the latest SEC disclosures
Roughly 24.0% of the company shares are held by company insiders
Latest headline from news.google.com: DRMAW - Dermata Therapeutics Inc Latest Stock News Market Updates - Stock Titan

Dermata Therapeutics Upcoming and Recent Events

Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Dermata Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
20th of February 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Dermata Largest EPS Surprises

Earnings surprises can significantly impact Dermata Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2023-11-09
2023-09-30-0.63-0.540.0914 
2024-12-31
2024-12-31-1.5-1.340.1610 
2023-08-10
2023-06-30-0.92-0.630.2931 
View All Earnings Estimates

Dermata Therapeutics Thematic Classifications

In addition to having Dermata Therapeutics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Pharmaceutical Products Idea
Pharmaceutical Products
USA Equities from Pharmaceutical Products industry as classified by Fama & French

Dermata Stock Institutional Investors

Shares
Armistice Capital, Llc2024-12-31
27.2 K
Ubs Group Ag2024-12-31
13.9 K
Wells Fargo & Co2024-12-31
K
Tower Research Capital Llc2024-12-31
1.4 K
Sbi Securities Co Ltd2024-12-31
1000
Bank Of America Corp2024-12-31
16.0
Note, although Dermata Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Dermata Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.46 M.

Dermata Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets-3.5 K-3.3 K
Return On Capital Employed-8 K-7.6 K
Return On Assets-3.5 K-3.3 K
Return On Equity(7.87)(7.48)

Management Efficiency

Dermata Therapeutics has return on total asset (ROA) of (1.3587) % which means that it has lost $1.3587 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.1044) %, meaning that it created substantial loss on money invested by shareholders. Dermata Therapeutics' management efficiency ratios could be used to measure how well Dermata Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -3,303. The current year's Return On Capital Employed is expected to grow to -7,615. At present, Dermata Therapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 7.3 M, whereas Other Current Assets are forecasted to decline to about 483.3 K.
Last ReportedProjected for Next Year
Book Value Per Share 1.02  0.97 
Tangible Book Value Per Share 1.02  0.97 
Enterprise Value Over EBITDA 0.09  0.09 
Enterprise Value Multiple 0.09  0.09 
Enterprise Value-1.3 M-1.2 M
Dermata Therapeutics has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Beta
0.578
Return On Assets
(1.36)
Return On Equity
(3.10)

Technical Drivers

As of the 3rd of May, Dermata Therapeutics shows the Standard Deviation of 4.98, variance of 24.81, and Mean Deviation of 3.75. Dermata Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.

Dermata Therapeutics Price Movement Analysis

The output start index for this execution was thirty-two with a total number of output elements of twenty-nine. The MESA Adaptive Moving Average indicator adapts to Dermata Therapeutics price movement based on the rate change of phase as measured by the Hilbert Transform Discriminator.

Dermata Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Dermata Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Dermata Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Dermata Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Scott Kathleen D. over a month ago
Acquisition by Scott Kathleen D. of 5826 shares of Dermata Therapeutics subject to Rule 16b-3
 
Gerald Proehl over a month ago
Acquisition by Gerald Proehl of 45000 shares of Dermata Therapeutics at 1.38 subject to Rule 16b-3
 
Van Hoose Kyri K. over a month ago
Acquisition by Van Hoose Kyri K. of 30000 shares of Dermata Therapeutics at 1.88 subject to Rule 16b-3
 
Fisher Mary over two months ago
Acquisition by Fisher Mary of 8602 shares of Dermata Therapeutics subject to Rule 16b-3
 
David Hale over three months ago
Acquisition by David Hale of 78741 shares of Dermata Therapeutics subject to Rule 16b-3
 
David Hale over three months ago
Acquisition by David Hale of 78741 shares of Dermata Therapeutics at 1.27 subject to Rule 16b-3
 
Scott Kathleen D. over three months ago
Acquisition by Scott Kathleen D. of 5000 shares of Dermata Therapeutics at 1.38 subject to Rule 16b-3
 
Scott Kathleen D. over six months ago
Acquisition by Scott Kathleen D. of 10000 shares of Dermata Therapeutics at 0.6099 subject to Rule 16b-3
 
Sandler Andrew Seth over six months ago
Acquisition by Sandler Andrew Seth of 5000 shares of Dermata Therapeutics at 1.88 subject to Rule 16b-3
 
Gerald Proehl over a year ago
Acquisition by Gerald Proehl of 27987 shares of Dermata Therapeutics at 20.5 subject to Rule 16b-3
 
Gerald Proehl over a year ago
Dermata Therapeutics exotic insider transaction detected
 
Nardo Christopher J over a year ago
Acquisition by Nardo Christopher J of 100000 shares of Dermata Therapeutics subject to Rule 16b-3

Dermata Therapeutics Outstanding Bonds

Dermata Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Dermata Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Dermata bonds can be classified according to their maturity, which is the date when Dermata Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Dermata Therapeutics Predictive Daily Indicators

Dermata Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Dermata Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Dermata Therapeutics Forecast Models

Dermata Therapeutics' time-series forecasting models are one of many Dermata Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Dermata Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Dermata Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Dermata Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Dermata shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Dermata Therapeutics. By using and applying Dermata Stock analysis, traders can create a robust methodology for identifying Dermata entry and exit points for their positions.
Last ReportedProjected for Next Year

Current Dermata Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Dermata analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Dermata analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
6.0Buy1Odds
Dermata Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Dermata analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Dermata stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Dermata Therapeutics, talking to its executives and customers, or listening to Dermata conference calls.
Dermata Analyst Advice Details

Dermata Stock Analysis Indicators

Dermata Therapeutics stock analysis indicators help investors evaluate how Dermata Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Dermata Therapeutics shares will generate the highest return on investment. By understating and applying Dermata Therapeutics stock analysis, traders can identify Dermata Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow7.4 B
Net Debt-3.2 M
50 Day M A1.034
Total Current LiabilitiesM
Common Stock Shares Outstanding1.5 M
Total Stockholder Equity1.6 B
Cash And Short Term Investments3.2 B
Cash3.2 M
Stock Based Compensation657.6 M
Accounts Payable808 K

Complementary Tools for Dermata Stock analysis

When running Dermata Therapeutics' price analysis, check to measure Dermata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermata Therapeutics is operating at the current time. Most of Dermata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dermata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermata Therapeutics' price. Additionally, you may evaluate how the addition of Dermata Therapeutics to your portfolios can decrease your overall portfolio volatility.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Commodity Directory
Find actively traded commodities issued by global exchanges